In the last 12 months, insiders at Editas Medicine made open-market sales of $106,726 (41.86K shares) and bought no shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Gilmore Neil O'Neill | Ceo | 286,756 | 0 | 286,756 | 28.2% | 06 Nov, 2026 |
| 2 | Baisong Mei | Evp, Chief Medical Officer | 133,354 | 0 | 133,354 | 13.1% | 05 Dec, 2024 |
| 3 | Erick Lucera | Evp, Chief Financial Officer | 112,720 | 0 | 112,720 | 11.1% | 05 Mar, 2025 |
| 4 | Michelle Robertson | Evp, Chief Financial Officer | 106,610 | 0 | 106,610 | 10.5% | 15 May, 2023 |
| 5 | Linda Burkly | Evp, Chief Scientific Officer | 78,193 | 0 | 78,193 | 7.7% | 06 Nov, 2026 |
| 6 | James C Mullen | Ceo | 75,898 | 0 | 75,898 | 7.5% | 04 Jan, 2022 |
| 7 | Bruce Eaton | Evp, Cbo And Cto | 74,791 | 0 | 74,791 | 7.4% | 07 Dec, 2023 |
| 8 | Jessica Hopfield | Director | 67,700 | 0 | 67,700 | 6.7% | 14 May, 2024 |
| 9 | Mark S Shearman | Evp, Chief Scientific Officer | 65,559 | 0 | 65,559 | 6.5% | 15 Feb, 2023 |
| 10 | Amy Parison | Svp, Chief Financial Officer | 13,839 | 0 | 13,839 | 1.4% | 04 Sep, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 05 Nov, 2026 | Gilmore Neil O'Neill | Ceo | Acquired A | 43,567 | $0.00 | $0 | 286,756 | Direct |
| 05 Nov, 2026 | Linda Burkly | Evp, Chief Scientific Officer | Acquired A | 16,533 | $0.00 | $0 | 78,193 | Direct |
| 08 Sep, 2026 | Daniel Scott Ory | Evp, Chief Medical Officer | Acquired A | 950,000 | $0.00 | $0 | 950,000 | Direct |
| 03 Sep, 2026 | Linda Burkly | Evp, Chief Scientific Officer | Disposed S | 709 | $3.04 | $2.15K | 61,660 | Direct |
| 03 Sep, 2026 | Amy Parison | Svp, Chief Financial Officer | Disposed S | 453 | $3.04 | $1.38K | 13,839 | Direct |
| 03 Sep, 2026 | Gilmore Neil O'Neill | Ceo | Disposed S | 5,124 | $3.04 | $15.56K | 243,189 | Direct |
| 06 Aug, 2026 | Patrick Thomas Ii Ellinor | Director | Acquired A | 103,400 | $0.00 | $0 | 103,400 | Direct |
| 03 Aug, 2026 | Amy Parison | Svp, Chief Financial Officer | Disposed S | 678 | $2.58 | $1.75K | 14,292 | Direct |
| 28 Jul, 2026 | Linda Burkly | Evp, Chief Scientific Officer | Disposed S | 4,928 | $2.67 | $13.16K | 62,369 | Direct |
| 17 Jun, 2026 | Andrew Hirsch | Director | Acquired A | 51,700 | $0.00 | $0 | 51,700 | Direct |
| 17 Jun, 2026 | Elliott M. Levy | Director | Acquired A | 51,700 | $0.00 | $0 | 51,700 | Direct |
| 17 Jun, 2026 | David Scadden | Director | Acquired A | 51,700 | $0.00 | $0 | 51,700 | Direct |
| 17 Jun, 2026 | Bernadette Connaughton | Director | Acquired A | 51,700 | $0.00 | $0 | 51,700 | Direct |
| 17 Jun, 2026 | Jessica Hopfield | Director | Acquired A | 51,700 | $0.00 | $0 | 51,700 | Direct |
| 03 Jun, 2026 | Gilmore Neil O'Neill | Ceo | Disposed S | 15,380 | $2.70 | $41.54K | 248,313 | Direct |
| 03 Jun, 2026 | Amy Parison | Svp, Chief Financial Officer | Disposed S | 464 | $2.70 | $1.25K | 14,970 | Direct |
| 03 Jun, 2026 | Linda Burkly | Evp, Chief Scientific Officer | Disposed S | 731 | $2.70 | $1.97K | 67,297 | Direct |
| 12 Mar, 2026 | Gilmore Neil O'Neill | Ceo | Acquired A | 1,015,200 | $0.00 | $0 | 1,015,200 | Direct |
| 12 Mar, 2026 | Linda Burkly | Evp, Chief Scientific Officer | Acquired A | 292,856 | $0.00 | $0 | 292,856 | Direct |
| 12 Mar, 2026 | Amy Parison | Svp, Chief Financial Officer | Acquired A | 292,856 | $0.00 | $0 | 292,856 | Direct |